Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor

PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and a model of targeted molecular therapy. GIST depends on oncogenic KIT signaling and responds to the tyrosine kinase inhibitor imatinib. However, imatinib is rarely curative. We hypothesized that PLX3397, which inhibit...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kim, Teresa S., Cavnar, Michael J., Cohen, Noah A., Sorenson, Eric C., Greer, Jonathan B., Seifert, Adrian M., Crawley, Megan H., Green, Benjamin L., Popow, Rachel, Pillarsetty, Nagavarakishore, Veach, Darren R., Ku, Anson T., Rossi, Ferdinand, Besmer, Peter, Antonescu, Cristina R., Zeng, Shan, DeMatteo, Ronald P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2014
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008656/
https://ncbi.nlm.nih.gov/pubmed/24583793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3033
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg